1266 related articles for article (PubMed ID: 24060603)
1. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab in chronic urticaria.
Metz M; Maurer M
Curr Opin Allergy Clin Immunol; 2012 Aug; 12(4):406-11. PubMed ID: 22766620
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria.
Har D; Patel S; Khan DA
Ann Allergy Asthma Immunol; 2015 Aug; 115(2):126-9. PubMed ID: 26093778
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria.
Song CH; Stern S; Giruparajah M; Berlin N; Sussman GL
Ann Allergy Asthma Immunol; 2013 Feb; 110(2):113-7. PubMed ID: 23352531
[TBL] [Abstract][Full Text] [Related]
7. Real-life experiences with omalizumab for the treatment of chronic urticaria.
Sussman G; Hébert J; Barron C; Bian J; Caron-Guay RM; Laflamme S; Stern S
Ann Allergy Asthma Immunol; 2014 Feb; 112(2):170-4. PubMed ID: 24468258
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K
J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
10. Ligelizumab for Chronic Spontaneous Urticaria.
Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
[TBL] [Abstract][Full Text] [Related]
11. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab in the treatment of chronic urticaria.
Francés L; Leiva-Salinas M; Silvestre JF
Actas Dermosifiliogr; 2014; 105(1):45-52. PubMed ID: 23938072
[TBL] [Abstract][Full Text] [Related]
13. The potential role of omalizumab in the treatment of chronic urticaria.
Stitt JM; Dreskin SC
Immunotherapy; 2014; 6(6):691-7. PubMed ID: 25186602
[TBL] [Abstract][Full Text] [Related]
14. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria.
Metz M; Ohanyan T; Church MK; Maurer M
JAMA Dermatol; 2014 Mar; 150(3):288-90. PubMed ID: 24477320
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice.
Labrador-Horrillo M; Valero A; Velasco M; Jáuregui I; Sastre J; Bartra J; Silvestre JF; Ortiz de Frutos J; Gimenez-Arnau A; Ferrer M
Expert Opin Biol Ther; 2013 Sep; 13(9):1225-8. PubMed ID: 23875845
[TBL] [Abstract][Full Text] [Related]
16. Treatment of severely recalcitrant chronic spontaneous urticaria: a discussion of relevant issues.
Wieder S; Maurer M; Lebwohl M
Am J Clin Dermatol; 2015 Feb; 16(1):19-26. PubMed ID: 25452254
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
[TBL] [Abstract][Full Text] [Related]
19. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
Chang TW; Chen C; Lin CJ; Metz M; Church MK; Maurer M
J Allergy Clin Immunol; 2015 Feb; 135(2):337-42. PubMed ID: 24948369
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab in Chronic Urticaria: An Italian Survey.
Damiani G; Diani M; Conic RRZ; Colli L; Ferrucci S; Martina E; Offidani AM; Pigatto PDM
Int Arch Allergy Immunol; 2019; 178(1):45-49. PubMed ID: 30396176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
